Retinopathy of prematurity: Involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical reintervention

Transactions of the American Ophthalmological Society

Volumn 103, Issue , 2005, Pages 281-312

  Coats, David K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HIGH RISK POPULATION; HUMAN; INFANT; INVOLUTION; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; LASER SURGERY; LASER THERAPY; LOGISTIC MODELS; MALE; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETINAL DETACHMENT; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; RISK FACTORS; VITRECTOMY; VITREOUS BODY;

EID: 29944436286     PISSN: 15456110     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020 - the right to sight. Bull World Health Organ 2001;79:227-232.
2. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. Am J Ophthalmol 1942;25:203-204.
3. Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in premature infants. II. Report of case - clinical aspects. Arch Ophthalmol 1943;29:36-53.
4. Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in premature infants. III. Report of cases - etiologic factors. Arch Ophthalmol. 1943;29:54-68.
5. Silverman WA. Retrolental Fibroplasia. A Modern Parable. New York: Grune & Stratton; 1980.
6. Hess JH. Oxygen unit for premature and very young infants. Am J Dis Child 1934;47:916-917.
7. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust 1951;2:48-50.
8. Patz A, Hoech LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952;35:1248-1253.
9. Kinsey VE, Jacobus JT, Hemphill FM. Retrolental fibroplasia. Cooperative study of retrolental fibroplasia and the use of oxygen. Arch Ophthalmol 1956;56:481-547.
10. Patz A, Eastham A, Higginbotham DH, et al. Oxygen studies in retrolental fibroplasia. II. The production of the microscopic changes of retrolental fibroplasia in experimental animals. Am J Ophthalmol 1953;36:1511-1522.
11. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol 1954;38:397-432.
12. Dollery CT, Bulpitt CJ, Kohner EM. Oxygen supply to the retina from the retinal and choroidal circulations at normal and increased arterial oxygen tensions. Invest Ophthalmol 1969;8:588-594.
13. Chan-Ling T, Tout S, Hollander H, et al. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1992;33:2128-2147.
14. Katz ML, Robison WG Jr. Autoxidative damage to the retina: potential role in retinopathy of prematurity. Birth Defects Orig Artic Ser 1988;24:237-248.
15. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-1228.
16. Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003;112:1016-1020.
17. Avery ME, Oppenheimer EH. Recent increase in mortality from hyaline membrane disease. J Pediatr 1960;57:553-559.
18. Hatfield EM. Blindness in infants and young children. Sight Sav Rev 1972;42:69-89.
19. Cross KW. Cost of preventing retrolental fibroplasia? Lancet 1973;2:954-956.
20. Nelson KB, Grether JK. Causes of cerebral palsy. Curr Opin Pediatr 1999;11:487-491.
21. Patz A. The need for further research in retrolental fibroplasia. Sight Sav Rev 1970;40:7-11.
22. Bolton DP, Cross KW. Further observations on cost of preventing retrolental fibroplasia. Lancet 1974;1:445-448.
23. Bauer CR. The occurence of retrolental fibroplasia in infants of birth weight 1000 grams and less (abstract). Clin Res 1978;26:824A.
24. Gunn TR, Aranda JV, Little J. Incidence of retrolental fibroplasia. Lancet 1978;1:216-217.
25. McCormick AQ. Retinopathy of prematurity. Curr Probl Pediatr 1977;7:1-28.
26. Emsley HC, Wardle SP, Sims DG, et al. Increased survival and deteriorating developmental outcome in 23 to 25 week old gestation infants, 1990-4 compared with 1984-9. Arch Dis Child Fetal Neonatal Ed 1998;78:F99-104.
27. Uemura Y. Current status of retrolental fibroplasia. Report of the Joint Committee for the Study of Retrolental Fibroplasia in Japan. Jpn J Ophthalmol 1977;21:366-378.
28. Sasaki K, Yamashita Y, Maekawa T, et al. Treatment of retinopathy of prematurity in active stage by cryocautery. Jpn J Ophthalmol 1976;20:384-395.
29. Hindle NW. Cryotherapy for retinopathy of prematurity to prevent retrolental fibroplasia. Can J Ophthalmol 1982;17:207-212.
30. Mousel DK, Hoyt CS. Cryotherapy for retinopathy of prematurity. Ophthalmology 1980;87:1121-1127.
31. Ben-Sira I, Nissenkorn I, Grunwald E, et al. Treatment of acute retrolental fibroplasia by cryopexy. Br J Ophthalmol 1980;64:758-762.
32. Keith CG. Visual outcome and effect of treatment in stage III developing retrolental fibroplasia. Br J Ophthalmol 1982;66:446-449.
33. Kingham JD. Acute retrolental fibroplasia. II. Treatment by cryosurgery. Arch Ophthalmol 1978;96:2049-2053.
34. Harris GS, McCormick AQ. The prophylactic treatment of retrolental fibroplasia. Mod Probl Ophthalmol 1977;18:364-367.
35. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome - structure and function. Arch Ophthalmol 1990;108:1408-1416.
36. Rowlands E, Ionides AC, Chinn S, et al. Reduced incidence of retinopathy of prematurity. Br J Ophthalmol 2001;85:933-935.
37. Bullard SR, Donahue SP, Feman SS, et al. The decreasing incidence and severity of retinopathy of prematurity. J AAPOS 1999;3:46-52.
38. Reynolds JD, Hardy RJ, Palmer EA. Incidence and severity of retinopathy of prematurity [letter]. J Aapos 1999;3:321-322.
39. Oishi M, Nishida H, Sasaki T. Japanese experience with micropremies weighing less than 600 grams born between 1984 to 1993. Pediatrics 1997;99:E7.
40. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991;98:1628-1640.
41. Coats DK, Paysse EA, Steinkuller PG. Threshold retinopathy of prematurity in neonates less than 25 weeks' estimated gestational age. J AAPOS 2000;4:183-185.
42. O'Connor AR, Stephenson T, Johnson A, et al. Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 2002;109:12-18.
43. Rudanko SL, Fellman V, Laatikainen L. Visual impairment in children born prematurely from 1972 through 1989. Ophthalmology 2003;110:1639-1645.
44. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002;86:716-722.
45. Munoz B, West SK. Blindness and visual impairment in the Americas and the Caribbean. Br J Ophthalmol 2002;86:498-504.
46. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS 1999;3:26-32.
47. Gilbert C, Rahi J, Eckstein M, et al. Retinopathy of prematurity in middle-income countries. Lancet 1997;350:12-14.
48. Global Initiative for the Elimination of Avoidable Blindness. Vol WHO/PBL/97.61. Geneva: World Health Organization; 1998.
49. Chan K, Ohlsson A, Synnes A, et al. Survival, morbidity, and resource use of infants of 25 weeks' gestational age or less. Am J Obstet Gynecol 2001;185:220-226.
50. Msall ME, Buck GM, Rogers BT, et al. Predictors of mortality, morbidity, and disability in a cohort of infants < or = 28 weeks' gestation. Clin Pediatr (Phila) 1993;32:521-527.
51. Msall ME, Phelps DL, DiGaudio KM, et al. Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Behalf of the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Pediatrics 2000;106:998-1005.
52. Drummond MF. Economic aspects of cataract. Ophthalmology 1988;95:1147-1153.
53. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-1134.
54. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988;106:471-479.
55. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. II. The classification of retinal detachment. Arch Ophthalmol 1987;105:906-912.
56. Hittner HM, Godio LB, Rudolph AJ, et al. Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants. N Engl J Med 1981;305:1365-1371.
57. Finer NN, Schindler RF, Grant G, et al. Effect of intramuscular vitamin E on frequency and severity of retrolental fibroplasia. A controlled trial. Lancet 1982;1:1087-1091.
58. Johnson L, Schaffer D, Boggs TR Jr. The premature infant, vitamin E deficiency and retrolental fibroplasia. Am J Clin Nutr 1974;27:1158-1173.
59. Lakatos L, Lakatos Z, Hatvani I, et al. Controlled trial of use of D-Penicillamine to prevent retinopathy of prematurity in very low-birth-weight infants. In: Stern L, Oh W, Friis-Hansen B, eds. Physiologic Foundations of Perinatal Care. Vol 2. New York: Elsevier; 1987:9-23.
60. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I. Primary outcomes. Pediatrics 2000;105:295-310.
61. Cunningham S, Fleck BW, Elton RA, et al. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 1995;346:1464-1465.
62. Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003;111:339-345.
63. Reynolds JD, Hardy RJ, Kennedy KA, et al. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N Engl J Med 1998;338:1572-1576.
64. Wallace DK, Coats DK, Paysse EA. Retinopathy of prematurity survey results [letter]. J AAPOS 1998;2:65-66.
65. Davis AR, Jackson H, Trew D, et al. Transscleral diode laser in the treatment of retinopathy of prematurity. Eye 1999;13(Pt 4):571-576.
66. Seiberth V, Linderkamp O, Vardarli I. Transscleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 1997;115:1270-1275.
67. McNamara JA, Tasman W, Brown GC, et al. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology 1991;98:576-580.
68. McNamara JA, Tasman W, Vander JF, et al. Diode laser photocoagulation for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1992;110:1714-1716.
69. O'Keefe M, O'Reilly J, Lanigan B. Longer-term visual outcome of eyes with retinopathy of prematurity treated with cryotherapy or diode laser. Br J Ophthalmol 1998;82:1246-1248.
70. DeJonge MH, Ferrone PJ, Trese MT. Diode laser ablation for threshold retinopathy of prematurity: short-term structural outcome. Arch Ophthalmol 2000;118:365-367.
71. White JE, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome. J Pediatr Ophthalmol Strabismus 1997;34:83-87; quiz 121-122.
72. Hammer ME, Pusateri TJ, Hess JB, et al. Threshold retinopathy of prematurity. Transition from cryopexy to laser treatment. Retina 1995;15:486-489.
73. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology 1993;100:238-244.
74. Paysse EA, Lindsey JL, Coats DK, et al. Therapeutic outcomes of cryotherapy versus transpupillary diode laser photocoagulation for threshold retinopathy of prematurity. J Aapos 1999;3:234-240.
75. Connolly BP, Ng EY, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002;109:936-941.
76. Ng EY, Connolly BP, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002;109:928-934; discussion 935.
77. Noonan CP, Clark DI. Trends in the management of stage 3 retinopathy of prematurity. Br J Ophthalmol 1996;80:278-281.
78. Capone A, Jr, Diaz-Rohena R, Sternberg P Jr, et al. Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993;116:444-450.
79. O'Neil JW, Hutchinson AK, Saunders RA, et al. Acquired cataracts after argon laser photocoagulation for retinopathy of prematurity. J Aapos 1998;2:48-51.
80. Paysse EA, Miller A, Brady McCreery KM, et al. Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology 2002;109:1662-1665.
81. Fleming TN, Runge PE, Charles ST. Diode laser photocoagulation for prethreshold, posterior retinopathy of prematurity. Am J Ophthalmol 1992;114:589-592.
82. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.
83. Schulenburg WE, Prendiville A, Ohri R. Natural history of retinopathy of prematurity. Br J Ophthalmol 1987;71:837-843.
84. Flynn JT, Bancalari E, Bachynski BN, et al. Retinopathy of prematurity. Diagnosis, severity, and natural history. Ophthalmology 1987;94:620-629.
85. Preslan MW, Butler J. Regression pattern in retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 1994;31:172-176.
86. Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 2000;118:645-649.
87. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1993;100:230-237.
88. Friedman S, Richardson SE, Jacobs SE, et al. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504.
89. Mittal M, Dhanireddy R, Higgins RD. Candida sepsis and association with retinopathy of prematurity. Pediatrics 1998;101:654-657.
90. Noyola DE, Bohra L, Paysse EA, et al. Association of candidemia and retinopathy of prematurity in very low birth-weight infants. Ophthalmology 2002;109:80-84.
91. Karlowicz MG, Giannone PJ, Pestian J, et al. Does candidemia predict threshold retinopathy of prematurity in extremely low birth weight (
92. Flynn JT, Cassady J, Essner D, et al. Fluorescein angiography in retrolental fibroplasia: experience from 1969-1977. Ophthalmology 1979;86:1700-1723.
93. Hikichi T, Nomiyama G, Ikeda H, et al. Vitreous changes after treatment of retinopathy of prematurity. Jpn J Ophthalmol 1999;43:543-545.
94. Faris B, Tolentino FI, Freeman HM, et al. Retrolental fibroplasia in the cicatricial stage. Fundus and vitreous findings. Arch Ophthalmol 1971;85:661-668.
95. Foos RY. Chronic retinopathy of prematurity. Ophthalmology 1985;92:563-574.
96. Hirose T, Sang DN. Vitreous changes in retinopathy of prematurity. Bull Soc Belge Ophtalmol 1987;223 Pt 1:165-177.
97. deJuan E Jr, Machemer R. Retinopathy of prematurity. Surgical technique. Retina 1987;7:63-69.
98. Soong HK, Eller AW, Hirose T, et al. In situ actin distribution in excised retrolental membranes in retinopathy of prematurity. Arch Ophthalmol 1985;103:1553-1556.
99. Flynn JT, O'Grady GE, Herrera J, et al. Retrolental fibroplasia: I. Clinical observations. Arch Ophthalmol 1977;95:217-223.
100. Gilbert WS, Quinn GE, Dobson V, et al. Partial retinal detachment at 3 months after threshold retinopathy of prematurity. Long-term structural and functional outcome. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1996;114:1085-1091.
101. Hartnett ME, McColm JR. Retinal features predictive of progressive stage 4 retinopathy of prematurity. Retina 2004;24:237-241.
102. Fuchino Y, Hayashi H, Kono T, et al. Long-term follow up of visual acuity in eyes with stage 5 retinopathy of prematurity after closed vitrectomy. Am J Ophthalmol 1995;120:308-316.
103. Quinn GE, Dobson V, Barr CC, et al. Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1996;103:595-600.
104. Capone A Jr, Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. Ophthalmology 2001;108:2068-2070.
105. Chandran R, Worrall MA, Sun R, et al. Combined lens-sparing vitrectomy and sclreal buckling in stage 4 retinopathy of prematurity with significant vitreoretinal traction (abstract). Invest Ophthalmol Vis Sci 2002;43:E-Abstract 4016.
106. Moshfeghi AA, Banach MJ, Salam GA, et al. Lens-sparing vitrectomy for tractional stage 4A retinopathy of prematurity retinal detachments (abstract). Invest Ophthalmol Vis Sci 2003;44:E-Abstract 604.
107. Cherwek DH, O'Keefe JS, Burian G, et al. Lens-sparing vitrectomy for tractional retinal detachment due to retinopathy of prematurity (ROP) (abstract). Invest Ophthalmol Vis Sci 2003;44:E-Abstract 605.
108. Kucey DS. Decision analysis for the surgeon. World J Surg 1999;23:1227-1231.
109. Elwyn G, Edwards A, Eccles M, et al. Decision analysis in patient care. Lancet 2001;358:571-574.
110. American Academy of Pediarics, Section on Ophthalmology. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2001;108:809-811.
111. Wallace DK, Kylstra JA, Chesnutt DA. Prognostic significance of vascular dilation and tortuosity insufficient for plus disease in retinopathy of prematurity. J Aapos 2000;4:224-229.
112. Quinn GE, Dobson V, Biglan A, et al. Correlation of retinopathy of prematurity in fellow eyes in the cryotherapy for retinopathy of prematurity study. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1995;113:469-473.
113. Cleves MA, Gould MW, Gutierrez RG. An Introduction to Survival Analysis Using Stata, Revised Edition. College Station, Texas: Stata Press; 2004.
114. Cocchiarella L, Andersson GGJ. Guides to the Evaluation of Permanent Impairment. 5th ed. USA: AMA Press; 2001.
115. Hartnett ME. Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina 2003;23:322-329.
116. Coats DK, Miller AM, Brady McCreery KM, et al. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 2004;111:1894-1898.
117. Hallman M, Bry K, Hoppu K, et al. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 1992;326:1233-1239.
118. Friedman CA, McVey J, Borne MJ, et al. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. J Pediatr Ophthalmol Strabismus 2000;37:79-86.
119. Tasman W. Threshold retinopathy of prematurity revisited. Arch Ophthalmol 1992;110:623-624.
120. Shaikh S, Capone A Jr, Schwartz SD, et al. Inadvertent skip areas in treatment of zone 1 retinopathy of prematurity. Retina 2003;23:128-131.
121. Mintz-Hittner HA, Kretzer FL. The rationale for cryotherapy with a prophylactic scleral buckle for Zone I threshold retinopathy of prematurity. Doc Ophthalmol 1990;74:263-268.
122. Kretzer FL, Hittner HM. Pathogenesis and antioxidant suppression of retinopathy of prematurity. In: Miquel J, Quintanilha AT, Weber H, eds. Handbook of Free Radicals and Antioxidants in Biomedicine. Vol II. Boca Raton, Florida: CRC Press; 2000:325.
123. Hutcheson KA, Nguyen AT, Preslan MW, et al. Vitreous hemorrhage in patients with high-risk retinopathy of prematurity. Am J Ophthalmol 2003;136:258-263.
124. Ehrenberg M, Thresher RJ, Machemer R. Vitreous hemorrhage nontoxic to retina as a stimulator of glial and fibrous proliferation. Am J Ophthalmol 1984;97:611-626.
125. de Juan E Jr, Shields S, Machemer R. The role of ultrasound in the management of retinopathy of prematurity. Ophthalmology 1988;95:884-888.
126. Pulido JS, Byrne SF, Clarkson JG, et al. Evaluation of eyes with advanced stages of retinopathy of prematurity using standardized echography. Ophthalmology 1991;98:1099-1104.
127. Seaber JH, Machemer R, Eliott D, et al. Long-term visual results of children after initially successful vitrectomy for stage V retinopathy of prematurity. Ophthalmology 1995;102:199-204.
128. Cherry TA, Lambert SR, Capone A Jr. Electroretinographic findings in stage 5 retinopathy of prematurity after retinal reattachment. Retina 1995;15:21-24.
129. Topilow HW, Ackerman AL, Wang FM. The treatment of advanced retinopathy of prematurity by cryotherapy and scleral buckling surgery. Ophthalmology 1985;92:379-387.
130. Machemer R. Description and pathogenesis of late stages of retinopathy of prematurity. Ophthalmology 1985;92:1000-1004.
131. Machemer R, deJuan E. Retinopathy of prematurity: approaches to surgical therapy. Aust N Z J Ophthalmol 1990;18:47-56.
132. Steidl SM, Hirose T. Subretinal organization in stage 5 retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2003;241:263-268.
133. Bettman JW. Seven hundred medicolegal cases in ophthalmology. Ophthalmology 1990;97:1379-1384.
134. Sternberg P Jr, Lopez PF, Lambert HM, et al. Controversies in the management of retinopathy of prematurity. Am J Ophthalmol 1992;113:198-202.
135. O'Keefe M, Burke J, Algawi K, et al. Diode laser photocoagulation to the vascular retina for progressively advancing retinopathy of prematurity. Br J Ophthalmol 1995;79:1012-1014.
136. Tsitsis T, Tasman W, McNamara JA, et al. Diode laser photocoagulation for retinopathy of prematurity. Trans Am Ophthalmol Soc 1997;95:231-236; discussion 237-245.
137. Smiddy WE, Hernandez E. Histopathologic characteristics of diode laser-induced chorioretinal adhesions for experimental retinal detachment in rabbit eyes. Arch Ophthalmol 1992;110:1630-1633.
138. Young TL, Anthony DC, Pierce E, et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS 1997;1:105-110.
139. Ferrone PJ, Harrison C, Trese MT. Lens clarity after lens-sparing vitrectomy in a pediatric population. Ophthalmology 1997;104:273-278.
140. Trese MT. Enzymatic-assisted vitrectomy. Eye 2002;16:365-368.
141. Schwartz WB. Sounding board. Decision analysis: a look at the chief complaints. N Engl J Med 1979;300:556-559.